[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Fu
Hai Ying
HY
Department of Clinical Laboratory Science, School of Allied Health Sciences, Osaka University, Faculty of Medicine.
Kawano
Sunao
S
Tanimura
Hirohisa
H
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage; D017291:Clarithromycin; D002986:Clinical Trials as Topic; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008795:Metronidazole; D009853:Omeprazole / Q000008:administration & dosage*; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole